Anastrozole Tablets Market to Surpass US$ 347.7 Million by 2027

Global Anastrozole Tablets Market, By Type (Branded Anastrozole Tablets and Generic Anastrozole Tablets), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 278.1 million in 2020 and is expected to exhibit a CAGR of 2.8% over the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

The increasing research and development, clinical trials, license agreements, and merger-acquisitions are major factors that are expected to drive growth of the anastrozole tablets market over the forecast period.

Key players in the market are also focused on strategic collaborations and partnerships to expand their market presence. For instance, in May 2016, Sunshine Biopharma Inc., a pharmaceutical company focused on research, development, and commercialization of drugs for the treatment of various forms of cancer, announced that it signed a Cross Referencing Agreement with a major pharmaceutical company (company name undisclosed) for anastrozole, a prescription generic drug for treatment of breast cancer. Sunshine will market and sell this new pharmaceutical product under its own label.

The increasing research and developments for anastrozole tablets is expected to drive growth of the anastrozole tablets market over the forecast period. For instance, in June 2019, Jiangsu HengRui Medicine Co., Ltd. started a clinical trial to study the efficacy and safety of SHR6390 (new drug candidate) in combination with Letrozole or Anastrozole in patients with HR positive and HER2 negative advanced breast cancer. The study is in phase 3. This study involved more than 400 participants. The study is expected to complete in June 2022.

The increasing demand for anastrozole for treatment of breast cancer is expected to increase the anastrozole tablets market revenue. For instance, in 2018, AstraZeneca Plc reported US$ 212 million sales of Arimidex (Anastrozole tablets) worldwide in 2018.

Browse 25 Market Data Tables and 29 Figures spread through 167 Pages and in-depth TOC on Anastrozole Tablets Market, By Type (Branded Anastrozole Tablets and Generic Anastrozole Tablets), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Forecast to 2027"

To know the latest trends and insights related to anastrozole tablets market, click the link below:

https://www.coherentmarketinsights.com/market-insight/anastrozole-tablets-market-3818

Furthermore, increasing awareness about breast cancer is expected to drive growth of the anastrozole tablets market over the forecast period. For instance, according to the World Health Organization, the Breast Cancer Awareness Month is marked in countries across the world every October, which helps to increase attention and support for the awareness, early detection, and treatment as well as palliative care of this disease.

Key Takeaways of the Anastrozole Tablets Market:

• The anastrozole tablets market is expected to exhibit a CAGR of 2,8% over the forecast period (2020-2027), owing to increasing license agreements regarding sales of anastrozole tablets.
• Among type, the generic anastrozole tablets segment is expected to hold major revenue share in 2027 owing to increasing license agreements. For instance, in December 2016, Sunshine Biopharma Inc. announced that it signed a strategic alliance agreement with Atlas Pharma Inc., a fully certified Montreal-based company offering analytical testing and other services to the pharmaceutical industry. In addition, Atlas will provide warehousing, regulatory compliance, logistics, and quality control for Sunshine's recently announced generic pharmaceuticals sales operations. Sunshine Biopharma's recently announced generic pharmaceuticals portfolio includes SBI-Anastrozole, SBI-Letrozole, SBI-Bicalutamidea, and SBI-Finasteride.
• Major players operating in the anastrozole tablets market include AstraZeneca Plc, Zydus Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals, Natco Pharma, Fresenius Kabi, Accord Healthcare Ltd., Mylan N.V., Cipla Ltd., Apotex Inc., Zhejiang Hisun, Chongqing Huapont Pharmaceutical Co., Ltd., Zhejiang Wansheng Pharmaceutical Co. Ltd., and Yangtze River Pharmaceutical Group